Recent developments include the company reporting Q4 losses with revenue lagging estimates, showcasing its regenerative skincare product at a wellness show, completing enrollment in its Phase 2 clinical trial, and announcing positive FDA meeting outcomes supporting accelerated approval pathways.

• BioRestorative Therapies reported a Q4 loss with revenue below expectations [N1].
• The company showcased its regenerative skincare product at the Be+Well Beauty and Wellness Show [N5].
• In February 2026, BioRestorative completed enrollment of 99 patients in its Phase 2 clinical trial of BRTX-100 [S1].
• The company announced a positive outcome from a Type B meeting with the FDA regarding an accelerated biologics license application pathway for BRTX-100 [N7].

The company’s lead product candidate, BRTX-100, has advanced through Phase 2 clinical trials with preliminary data showing safety and potential efficacy in reducing pain and improving function in patients with degenerative disc disease. The FDA Fast Track designation and positive Type B meeting outcomes support regulatory progress. The initiation of Phase 3 enabling activities and plans to submit a Phase 3 IND indicate advancement toward potential commercialization. The ThermoStem Program targets large markets in metabolic disorders with issued patents in multiple jurisdictions. The commercial biocosmeceutical platform offers a revenue stream and potential expansion into FDA-approved biologic aesthetic products. Recent capital raises provide funding to support ongoing development activities.

The company has not generated significant revenues and reported substantial net losses and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern without additional financing. The current ratio below 1 indicates liquidity constraints. The company operates in a high-risk biotechnology sector with lengthy and costly clinical development and regulatory approval processes. There is uncertainty regarding the timing and success of clinical trials, regulatory approvals, and market acceptance. The company’s common stock is classified as a penny stock and is below Nasdaq’s minimum bid price requirement, which may limit liquidity and investor interest. Failure to secure additional financing could force curtailment or discontinuation of operations.

BioRestorative Therapies’ moat is based on its proprietary cell culture and delivery technologies, exclusive licenses for stem cell treatment of disc and spine conditions, and a portfolio of issued patents in multiple jurisdictions covering its Disc/Spine and ThermoStem programs. The company’s BRTX-100 product utilizes a proprietary hypoxic culturing process designed to enhance cell viability in the avascular environment of damaged discs. The company also holds exclusive rights to an investigational curved needle device for targeted cell delivery. These intellectual property assets, combined with clinical trial data and FDA Fast Track designation, provide barriers to entry. However, the company operates in a highly competitive and regulated biotechnology sector with significant clinical and regulatory risks.

• Financing Risk: The company requires significant additional financing to complete clinical trials and fund operations. Failure to obtain financing on reasonable terms could force curtailment or discontinuation of operations.
• Clinical and Regulatory Risk: The success of the company depends on the outcome of clinical trials and obtaining regulatory approvals, which are uncertain and may delay or prevent commercialization.
• Liquidity Risk: As of December 31, 2025, the company had a working capital deficit and a current ratio below 1, indicating potential liquidity challenges.
• Market and Listing Risk: The company’s common stock is classified as a penny stock and is below Nasdaq’s minimum bid price requirement, risking potential delisting and reduced liquidity.
• Operational Risk: The company’s business is dependent on key personnel, intellectual property rights, and the ability to scale manufacturing and commercialization.

• BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols primarily involving adult stem cells.
• The company’s lead program is the Disc/Spine Program with the investigational product BRTX-100, a cell therapy derived from autologous cultured mesenchymal stem cells from the patient’s bone marrow.
• BRTX-100 is intended for non-surgical treatment of chronic lower back pain from degenerative disc disease and chronic cervical discogenic pain.
• The company is conducting a Phase 2 clinical trial for BRTX-100 and has FDA IND clearance for cervical discogenic pain.
• BRTX-100 has received FDA Fast Track designation for chronic lumbar disc disease.
• Preliminary clinical data from Phase 2 trials show no serious adverse events or dose limiting toxicities and indicate functional improvement and pain reduction in patients.
• The company is developing a ThermoStem Program targeting metabolic disorders such as type 2 diabetes and obesity using brown adipose derived stem cells and exosomes.
• Patents have been issued in the US, Europe, Israel, and Japan related to the ThermoStem Program and Disc/Spine Program.
• BioRestorative operates a commercial biocosmeceutical platform with a cell-based secretome serum designed to reduce fine lines and wrinkles.
• The company has licensed an investigational curved needle device for delivering cells to the spine and discs, pending FDA approval.
• The company completed enrollment of 99 patients in the Phase 2 clinical trial of BRTX-100 as of February 2026.
• BioRestorative has raised capital through public offerings, warrant exercises, and at-the-market programs, with gross proceeds of $5 million in February 2026.
• As of December 31, 2025, the company had cash and equivalents of approximately $1.5 million and short-term investments of approximately $1.4 million.
• The current ratio as of December 31, 2025 was 0.84, indicating current liabilities exceed current assets.
• The company reported a net loss of $14.2 million for the year ended December 31, 2025, with an accumulated deficit of approximately $170 million.
• BioRestorative has not generated significant revenues to date.
• The company’s business plan requires significant additional financing to complete clinical trials and fund operations.
• The company faces substantial doubt about its ability to continue as a going concern within twelve months from the 10-K filing date.
• The company’s common stock is classified as a penny stock and is currently below Nasdaq’s minimum bid price requirement, with a compliance period until September 2026.
• The company has 14 employees and operates a cGMP ISO-7 certified clean room for product manufacturing.
• The company’s target customers upon regulatory approval include physicians skilled in spinal injections, hospitals, research institutions, pharmaceutical companies, and the military.
• The company’s BRTX-100 treatment process involves collecting bone marrow from the patient, culturing stem cells under hypoxic conditions, cryopreserving the cells, and injecting them into the damaged disc in an outpatient procedure.
• The company has announced positive outcomes from a Type B meeting with the FDA regarding an accelerated biologics license application pathway for BRTX-100.
• The company has initiated Phase 3 enabling activities aiming to submit a Phase 3 IND during 2026.
• The company announced a stock repurchase program authorized for up to $2 million, but no shares have been repurchased to date.
• The company hired key personnel in 2025 including a Head of Global Commercial Operations and a business development executive focused on technology commercialization.
• The company’s commercial biocosmeceutical product is engineered to reduce fine lines and wrinkles and may expand to a broader family of cell-based biologic aesthetic products and therapeutics.